Barry E. Greene's most recent trade in Karyopharm Therapeutics Inc was a trade of 4,600 Nonstatutory Stock Option (right to buy) done . Disclosure was reported to the exchange on May 28, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Karyopharm Therapeutics Inc | Barry E. Greene | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2025 | 4,600 | 4,600 | - | - | Nonstatutory Stock Option (right to buy) | |
| Sage Therapeutics Inc | Barry E. Greene | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Apr 2025 | 19,964 | 105,031 (0%) | 0% | 0 | Common Stock | |
| Sage Therapeutics Inc | Barry E. Greene | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.91 per share. | 10 Apr 2025 | 4,862 | 100,169 (0%) | 0% | 6.9 | 33,596 | Common Stock |
| Sage Therapeutics Inc | Barry E. Greene | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2025 | 174,000 | 174,000 | - | - | Stock Option (Right to Buy) | |
| Sage Therapeutics Inc | Barry E. Greene | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2024 | 50,400 | 97,340 (0%) | 0% | 0 | Common Stock | |
| Sage Therapeutics Inc | Barry E. Greene | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.96 per share. | 05 Aug 2024 | 12,273 | 85,067 (0%) | 0% | 9.0 | 109,966 | Common Stock |
| Karyopharm Therapeutics Inc | Barry E. Greene | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 69,000 | 69,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| Sage Therapeutics Inc | Barry E. Greene | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 168,000 | 168,000 | - | - | Stock Option (Right to Buy) | |
| Sage Therapeutics Inc | Barry E. Greene | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Aug 2023 | 195,000 | 195,000 | - | - | Stock Option (Right to Buy) | |
| Karyopharm Therapeutics Inc | Barry E. Greene | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2023 | 34,000 | 34,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| Sage Therapeutics Inc | Barry E. Greene | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 66,500 | 66,500 | - | - | Stock Option (Right to Buy) | |
| Sage Therapeutics Inc | Barry E. Greene | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 34.48 per share. | 10 Nov 2022 | 14,500 | 46,940 (0%) | 0% | 34.5 | 500,022 | Common Stock |
| Karyopharm Therapeutics Inc | Barry E. Greene | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2022 | 7,576 | 0 | - | - | Stock Option (right to buy) | |
| Karyopharm Therapeutics Inc | Barry E. Greene | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.48 per share. | 11 Aug 2022 | 7,576 | 13,606 (0%) | 0% | 1.5 | 11,250 | Common Stock |
| Karyopharm Therapeutics Inc | Barry E. Greene | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2022 | 23,900 | 23,900 | - | - | Nonstatutory Stock Option (right to buy) | |
| Sage Therapeutics Inc | Barry E. Greene | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2022 | 69,920 | 69,920 | - | - | Stock Option (Right to Buy) | |
| Sage Therapeutics Inc | Barry E. Greene | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 43.15 per share. | 05 Aug 2021 | 23,640 | 32,440 (0%) | 0% | 43.1 | 1,020,054 | Common Stock |
| Sage Therapeutics Inc | Barry E. Greene | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 56.32 per share. | 16 Jun 2021 | 8,800 | 8,800 (0%) | 0% | 56.3 | 495,627 | Common Stock |
| Acorda Therapeutics Inc | Barry E. Greene | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 10,000 | 10,000 | - | - | Non-Employee Stock Option | |
| Karyopharm Therapeutics Inc | Barry E. Greene | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2021 | 23,900 | 23,900 | - | - | Nonstatutory Stock Option (right to buy) | |
| Sage Therapeutics Inc | Barry E. Greene | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 390,000 | 390,000 | - | - | Stock Options (Right to buy) | |
| Alnylam Pharmaceuticals Inc | Barry E. Greene | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.14 per share. | 09 Sep 2020 | 44,530 | 114,873 (0%) | 0% | 9.1 | 407,004 | Common Stock |
| Alnylam Pharmaceuticals Inc | Barry E. Greene | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2020 | 44,530 | 0 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Barry E. Greene | President | Sale of securities on an exchange or to another person at price $ 123.39 per share. | 09 Sep 2020 | 27,109 | 73,689 (0%) | 0% | 123.4 | 3,344,980 | Common Stock |
| Alnylam Pharmaceuticals Inc | Barry E. Greene | President | Sale of securities on an exchange or to another person at price $ 122.66 per share. | 09 Sep 2020 | 14,075 | 100,798 (0%) | 0% | 122.7 | 1,726,440 | Common Stock |
| Alnylam Pharmaceuticals Inc | Barry E. Greene | President | Sale of securities on an exchange or to another person at price $ 124.38 per share. | 09 Sep 2020 | 3,346 | 70,343 (0%) | 0% | 124.4 | 416,175 | Common Stock |
| Alnylam Pharmaceuticals Inc | Barry E. Greene | President | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Sep 2020 | 3,176 | 0 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Barry E. Greene | President | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Sep 2020 | 3,176 | 65,412 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Barry E. Greene | President | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Sep 2020 | 155 | 3,176 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Barry E. Greene | President | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Sep 2020 | 155 | 3,331 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Barry E. Greene | President | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Sep 2020 | 155 | 155 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Barry E. Greene | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2020 | 1,587 | 88,413 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Barry E. Greene | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.00 per share. | 10 Aug 2020 | 1,587 | 63,823 (0%) | 0% | 63 | 99,981 | Common Stock |
| Alnylam Pharmaceuticals Inc | Barry E. Greene | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2020 | 1,184 | 23,816 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Barry E. Greene | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 42.22 per share. | 10 Aug 2020 | 1,184 | 67,167 (0%) | 0% | 42.2 | 49,988 | Common Stock |
| Alnylam Pharmaceuticals Inc | Barry E. Greene | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 88.95 per share. | 10 Aug 2020 | 1,124 | 65,983 (0%) | 0% | 89.0 | 99,980 | Common Stock |
| Alnylam Pharmaceuticals Inc | Barry E. Greene | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2020 | 1,124 | 38,876 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Barry E. Greene | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2020 | 1,036 | 46,589 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Barry E. Greene | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 96.45 per share. | 10 Aug 2020 | 1,036 | 64,859 (0%) | 0% | 96.4 | 99,922 | Common Stock |